Family · Pharmaceutical analytical standards
Tegoprazan
A potassium-competitive acid blocker (P-CAB), approved in South Korea in 2018 and marketed since 2019 for gastro-oesophageal reflux disease, ulcers and other acid-related disorders. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Unlike proton pump inhibitors, which bind the pump irreversibly, it competes with potassium and blocks the pump reversibly, with a rapid effect.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
